← ANALYST RATINGS · TIPRANKS
Arrowhead Pharmaceuticals (ARWR): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy1 Hold0 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $109, the highest $126, the lowest $74.00. The average is +95.0% from the last price of $55.90.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $60.00 → $61.00+1.7% | Hold | +9.1% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $61.00 → $62.00+1.6% | Hold | +10.9% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Buy | — | Reiterated | 15.10.26on TipRanks 08:10 | −0.1%next day −3.3% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $126 | Buy | +125.4% | Reiterated | 15.10.26on TipRanks 07:30 | −0.1%next day −3.3% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $108 | Buy | +93.2% | Reiterated | 14.10.26on TipRanks Oct 15 06:25 | +1.5%next day −0.1% | ↗ |
| Unknown Analyst | UBS | $63.00 → $109+73.0% | Buy | +95.0% | Assigned | 14.10.26on TipRanks Oct 15 06:25 | +1.5%next day −0.1% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $69.00 → $57.00−17.4% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $70.00 → $58.00−17.1% | Hold | +3.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $70.00 → $58.00−17.1% | Hold | +3.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $70.00 → $58.00−17.1% | Hold | +3.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $120 | Buy | +114.7% | Reiterated | 14.10.26on TipRanks 09:50 | +1.5%next day −0.1% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $100 | Buy | +78.9% | Reiterated | 12.10.26on TipRanks 08:40 | −3.2%next day −4.3% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $74.00 | Hold | +32.4% | Initiated | 24.09.26on TipRanks 06:30 | −1.2%next day −0.8% · 5 days −1.5% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $120 | Buy | +114.7% | Reiterated | 31.08.26on TipRanks Sep 1 07:30 | −2.7%next day +1.1% · 5 days +3.4% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $104 | Buy | +86.0% | Reiterated | 31.08.26on TipRanks 07:30 | −2.7%next day +1.1% · 5 days +3.4% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $100 | Buy | +78.9% | Reiterated | 30.08.26on TipRanks Aug 31 07:25 | −2.7%next day +1.1% · 5 days +3.4% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 30.08.26on TipRanks Aug 31 02:40 | −2.7%next day +1.1% · 5 days +3.4% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $123 | Buy | +120.0% | Reiterated | 05.08.26on TipRanks 08:55 | −2.8%next day −1.1% · 5 days 0.0% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $115 | Buy | +105.7% | Reiterated | 04.08.26on TipRanks 22:52 | −2.8%next day −1.1% · 5 days 0.0% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $35.00 → $46.00+31.4% | Hold | −17.7% | Assigned | 13.05.26on TipRanks 06:35 | −2.0%next day +1.5% · 5 days −0.8% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | — | Hold | — | Reiterated | 26.03.26on TipRanks 11:35 | +1.8%next day −3.2% · 5 days −1.2% | ↗ |
| Unknown Analyst | Jefferies | $67.00 | Buy | +19.9% | Reiterated | 05.12.25on TipRanks 09:10 | −5.2%next day +12.0% · 5 days +14.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Arrowhead Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $109 at a price of $62.75 (+73.9%); now: $109 at $55.90 (+95.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 1 | 0 | 1 | 6 |
| Buy | 14 | 19 | 30 | 35 | 33 | 20 |
| Hold | 2 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.11.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.52 (from $-3.00 to $-0.35). Last quarter: $-1.36.
Sales
Next quarter’s sales estimate — $61M (from $4M to $178M). Last quarter: $75M.
Best top-analyst consensus in the sector · Healthcare
About Arrowhead Pharmaceuticals
- CEO: Christopher R. Anzalone
- Employees: 711
- 177 East Colorado Boulevard, Pasadena, CA, 91105, US
- arrowheadpharma.com
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing
Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗